NEWCaplight raises a $16M Series A, led by BlackRock and Fin Capital →
Skip to main content
Caplight Logo









Endo Axiom

Endo Axiom

Private
SydneyHealthcare & Life Scienceshttps://www.endoaxiom.com/

Last Round

Grant

Jun 30, 2025

Total Funding Raised

$2.22M

Momentum

Top 25%

of companies Caplight tracks

Company Overview

Endo Axiom is a biotechnology company developing platforms for the oral delivery of drugs and biologics, including an oral smart insulin and an immune modulation platform to prevent type one diabetes.

Sector

Healthcare & Life Sciences

Verticals

EHR & EMR, Medical Imaging, Vertical SaaS

Business Model

B2B

Customer Profile

Services & Consulting

AI Layer

Non-AI

Keywords

biotechnologydrug deliveryoral insulinnanotechnologybiologicstherapeutic platformpreclinical researchclinical trialspharma pipelinebiotech startupdrug developmentoral drug delivery

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Endo Axiom Comparables

Compare Endo Axiom with similar companies based on industry and business-model similarity.

Endo Axiom comparables — related companies by embedding similarity
CompanySimilarityMarket Cap

View Full Comparables Set

Access detailed peer comparisons, similarity scores, and market data.

Endo Axiom Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
GrantJun 30, 2025
SeedApr 18, 2023

Key People

Founding team and executive leadership

Nicholas Hunt

Chief Executive Officer

Executive Team

Endo Axiom Investors

Notable investors and investment history

Endo Axiom investors
InvestorRounds
Proto AxiomSeed
MTPConnectGrant

Market signals

Structured signals derived from secondary market and firmographic data.

  • Jun 20, 2026

    Monthly visitors grew 106% MoM, reaching 2.4K.

  • May 16, 2026

    Monthly visitors increased 151% MoM, reaching 1.2K.

Endo Axiom Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Endo Axiom Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Endo Axiom's valuation, stock price, and market status.

Firmographic Details

HeadquartersSydney
Employee Range2
Year Founded2023
Last FundingJun 30, 2025

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.